Back to Search
RICHARD PAZDUR, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1619107596Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
D0060250(MD)
Research & Publications (20)
Recent advances in colorectal chemotherapy: oral fluorinated pyrimidines, oxaliplatin and irinotecan.
PMID 10779234·J Gastroenterol·2000
4-observational
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
PMID 19282350·Oncologist·2009
4-observational
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
PMID 19193781·Oncologist·2009
3-trial
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
PMID 19144678·Oncologist·2009
6-review
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
PMID 18922829·Oncologist·2008
4-observational
Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
PMID 18628451·Clin Cancer Res·2008
4-observational
Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
PMID 18519748·Clin Cancer Res·2008
1-meta
FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
PMID 18586926·Oncologist·2008
8-other
Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
PMID 18765523·Clin Cancer Res·2008
8-other
FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
PMID 18784156·Oncologist·2008
4-observational
Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy.
PMID 18448560·Oncologist·2008
8-other
FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia.
PMID 18305062·Oncologist·2008
4-observational
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
PMID 18316547·Clin Cancer Res·2008
4-observational
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
PMID 18849320·Oncologist·2008
3-trial
Expediting the availability of drugs for US patients with cancer.
PMID 19050708·Nat Clin Pract Urol·2008
6-review
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
PMID 18223208·Clin Cancer Res·2008
8-other
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
PMID 18247017·Oncology (Williston Park)·2007
3-trial
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
PMID 18077994·Oncology (Williston Park)·2007
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 10202 ADDISON CT
BETHESDA, MD 20817 - Phone
- (301) 897-5828
Quick Facts
- NPI
- 1619107596
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile